Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer

Drugs

Volumn 71, Issue 3, 2011, Pages 255-261

  Saylor, Philip J ^a   Keating, Nancy L ^b   Freedland, Stephen J ^c,d   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disorders; Diabetes mellitus; Gonadotropin releasing hormone stimulants; Prostate cancer; Radiotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ANDROGEN DEPRIVATION THERAPY; BODY MASS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MALE; METABOLIC RATE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORCHIECTOMY; PHYSICAL ACTIVITY; POPULATION BASED CASE CONTROL STUDY; POST HOC ANALYSIS; PRIMARY PREVENTION; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH; SURVIVAL RATE; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79951661266     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11588930-000000000-00000     Document Type: Review

References (48)

1. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009; 12 (4): 333-8.
2. FDA Drug Safety Communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases [online], http://www.fda.gov/Drugs/DrugSafety/ucm229986. htm#safety [Accessed 2011 Jan 19].
3. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 Jul 13; 360 (9327): 103-6.
4. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009 Jun 11; 360 (24): 2516-27.
5. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004 Aug 18; 292 (7): 821-7. (Pubitemid 39079668)
6. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005 Nov; 6 (11): 841-50. (Pubitemid 41614795)
7. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 Apr 1; 61 (5): 1285-90. (Pubitemid 40470408)
8. Horwitz EM, BaeK,Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008 May 20; 26 (15): 2497-504.
9. Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 1997 Oct; 158 (4): 1623-4.
10. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006 Jun; 7 (6): 472-9. (Pubitemid 43779173)
11. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009 Jan 1; 27 (1): 92-9.
12. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010 Jan 6; 102 (1): 39-46.
13. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 Sep 20; 24 (27): 4448-56. (Pubitemid 46630983)
14. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 Oct 1; 110 (7): 1493-500. (Pubitemid 47463063)
15. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007 Oct 17; 99 (20): 1516-24. (Pubitemid 351767235)
16. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 2010 Jul 20; 28 (21): 3448-56.
17. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009 Jul 20; 27 (21): 3452-8.
18. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010 Feb 16; 121 (6): 833-40.
19. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002 Feb; 87 (2): 599-603. (Pubitemid 34158224)
20. Smith MR. Changes in fat and lean body mass during androgen- deprivation therapy for prostate cancer. Urology 2004 Apr; 63 (4): 742-5. (Pubitemid 38479421)
21. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008 May 15; 112 (10): 2188-94. (Pubitemid 351628628)
22. Kim H, Moreira D, Smith M, et al. A natural history of weight change in men with prostate cancer on androgen deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. Epub 2010 Sep 22.
23. Smith MR, Lee H, Fallon MA, et al. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008 Feb; 71 (2): 318-22. (Pubitemid 351282338)
24. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006 Apr; 91 (4): 1305-8.
25. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003 Feb; 104 (2): 195-201. (Pubitemid 36238052)
26. Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008 Apr 10; 26 (11): 1824-9.
27. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995 Jul; 154 (1): 100-4.
28. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001 Sep; 86 (9): 4261-7. (Pubitemid 32848544)
29. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009 Jan; 32 Suppl. 1: S62-7.
30. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009 Aug 26; 302 (8): 866-73.
31. Roach 3rd M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: longterm results of RTOG 8610. J Clin Oncol 2008 Feb 1; 26 (4): 585-91. (Pubitemid 351264352)
32. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008 Oct; 54 (4): 816-23.
33. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 2006 Apr 20; 24 (12): 1868-76. (Pubitemid 46638985)
34. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007 Jun 10; 25 (17): 2420-5. (Pubitemid 46999213)
35. Roach 3rd M. Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol 2007 Nov 20; 25 (33): 5325-6; author reply 5326.
36. Brown BW, Brauner C,Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 1993 Jun 16; 85 (12): 979-87. (Pubitemid 23177584)
37. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010 Nov 4; 363 (19): 1822-32.
38. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008 Jul 9; 300 (2): 173-81. (Pubitemid 351969301)
39. Wong YN, Freedland SJ, Egleston B, et al. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009 Oct; 56 (4): 609-16.
40. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care 2010 Jan; 33 Suppl. 1: S11-61.
41. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 Feb 7; 346 (6): 393-403. (Pubitemid 34437694)
42. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009 Apr 17; 57 (14): 1-134.
43. Rosengren A, Dotevall A, Eriksson H, et al. Optimal risk factors in the population: prognosis, prevalence, and secular trends; data from Goteborg population studies. Eur Heart J 2001 Jan; 22 (2): 136-44. (Pubitemid 32619635)
44. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999 Dec 1; 282 (21): 2012-8.
45. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002 Jul 16; 106 (3): 388-91. (Pubitemid 34778969)
46. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-421.
47. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S12-54.
48. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 May 30; 373 (9678): 1849-60